Zuclopenthixol hydrochloride derivatives and Ebselen derivatives as ErbB2 inhibitors

Patent metadata

Field	Value
Publication number	US-10766873-B2
Application number	US-201716069049-A
Country	US
Kind code	B2
Filing date	Jan 11, 2017
Priority date	Jan 11, 2016
Publication date	Sep 8, 2020
Grant date	Sep 8, 2020

Abstract

The present invention relates to compounds of the following general formula (I) or (II): or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment and/or in the prevention of ErbB2 dependent cancers, and pharmaceutical compositions containing such compounds.

First claim

The invention claimed is:

1. A method of inhibiting ErbB2 activation in an ErbB2 dependent cancer patient, the method comprising:
selecting an ErbB2 dependent cancer patient that overexpresses ErbB2; and
administering to the ErbB2 dependent cancer patient an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof for inhibiting ErbB2 activation;
wherein compound (I) has the general formula:

wherein:
the symbol represents a bond in cis or trans configuration;
X is a sulfur atom;
R 1 is hydrogen atom, halo, —CN, —NO 2 , —NO, —CHO, —NR 7 R 8 , —CO 2 R 9 , —SO 2 R 10 , —SO 2 NR 11 R 12 , —OR 13 , —COR 14 , —SR 15 , —CONR 16 R 17 , —SO 2 (O)R 18 or a group selected from saturated (C 1 -C 6 )alkyl, unsaturated (C 1 -C 6 )alkyl and aryl, said group being optionally substituted with one or several groups selected from halo, —CF 3 , —CN and —SO 2 NR 19 R 20 ;
R 2 and R 3 form together with the nitrogen atom to which they are chemically linked a piperazinyl group substituted with one or several groups selected from halo, —CO 2 R 21 and a (C 1 -C 6 )alkyl group, the (C 1 -C 6 )alkyl group being optionally substituted with one or several groups selected from halo, —OR 22 , —SR 23 , —S(O)R 24 , —SO 2 R 25 , —SO 2 NR 26 R 27 , —OC(O)R 28 , —NR 29 COR 30 , —NR 31 CONR 32 R 33 , —NR 34 C(O)OR 35 , —CO 2 R 36 , —CONR 37 R 38 , —OCO 2 R 39 , —OCONR 40 R 41 , —COR 42 , —NO 2 , CF 3 , and —CN;
R 4 , R 5 and R 6 are, independently of one another, hydrogen atom, halo, —CN, —NO 2 , —NO, —CHO, —NR 43 R 44 , —CO 2 R 45 , —S(O)R 46 , —SO 2 R 47 , —SO 2 NR 48 R 49 , —OCOR 50 , —NR 51 COR 52 , —NR 53 CO(O)R 54 , —NR 55 CONR 56 R 57 , —CO 2 R 58 , —OR 59 , —COR 60 , —SR 61 , —CONR 62 R 63 , —OCONR 64 R 65 , —SO 2 (O)R 66 , or a group selected from saturated (C 1 -C 6 )alkyl, unsaturated (C 1 -C 6 )alkyl and aryl, said group being optionally substituted with one or several groups selected from halo, —CF 3 , —CN, and —SO 2 NR 67 R 68 ;
R 7 to R 68 are, independently of one another, a hydrogen atom or a (C 1 -C 10 )alkyl, aryl or aryl(C 1 -C 6 )alkyl group, said group being optionally substituted with one or several groups selected from halo, —OH, —CF 3 , —CN and SO 2 NR 69 R 70 ; with the proviso that R 21 is not an hydrogen atom;
R 69 and R 70 are independently of one another, a hydrogen atom or a (C 1 -C 10 )alkyl, aryl or aryl(C 1 -C 6 )alkyl group; and
n is an integer selected from 1 to 6.

2. The method according to claim 1 , wherein R 1 is hydrogen atom, halo, —CN, —NO 2 , —NO, —CHO, —NR 7 R 8 , —CO 2 R 9 , —SO 2 R 10 , —SO 2 NR 11 R 12 , —COR 14 , —CONR 16 R 17 , —SO 2 (O)R 18 or a group selected from saturated (C 1 -C 6 )alkyl, unsaturated (C 1 -C 6 )alkyl and aryl, said group being optionally substituted with one or several groups selected from halo, —CF 3 , —CN and —SO 2 NR 19 R 20 ; R 7 to R 12 , R 14 and R 16 to R 20 being as defined in claim 1 .

3. The method according to claim 1 , wherein R 1 is hydrogen atom, halo, —CN, —SO 2 NR 11 R 12 or —CF 3 ; R 11 and R 12 being as defined in claim 1 .

4. The method according to claim 1 , wherein R 2 and R 3 form together with the nitrogen atom to which they are chemically linked a piperazinyl group, substituted with one or several (C 1 -C 6 )alkyl group optionally substituted with one or several groups selected from —OR 22 , —SR 23 , —S(O)R 24 , —SO 2 R 25 , —SO 2 NR 26 R 27 , —OC(O)R 28 , —NR 29 COR 30 , —NR 31 CONR 32 R 33 , —NR 34 C(O)OR 35 , —CO 2 R 36 , —CONR 37 R 38 , —OCO 2 R 39 , —OCONR 40 R 41 , —COR 42 , —NO 2 and —CN; R 22 to R 42 being as defined in claim 1 .

5. The method according to claim 1 , wherein R 2 and R 3 form together with the nitrogen atom to which they are chemically linked a piperazinyl group, substituted with one (C 1 -C 6 )alkyl group optionally substituted with one or several groups selected from —OR 22 , —SR 23 , —S(O)R 24 , —SO 2 R 25 , —SO 2 NR 26 R 27 , —OC(O)R 28 , —OCO 2 R 39 and —COR 42 ; and wherein R 22 to R 28 , R 39 and R 42 are, independently of one another, a hydrogen atom or a (C 1 -C 10 )alkyl group.

6. The method according to claim 1 , wherein R 2 and R 3 form together with the nitrogen atom to which they are chemically linked a piperazinyl group, substituted with one (C 1 -C 6 )alkyl group optionally substituted with one group selected from —OR 22 and —OC(O)R 28 ;
and wherein R 22 , R 28 , and R 31 to R 33 are, independently of one another, a hydrogen atom or a (C 1 -C 6 )alkyl group.

7. The method according to claim 1 , wherein R 4 , R 5 and R 6 are, independently of one another, hydrogen atom, halo or (C 1 -C 6 )alkyl.

8. The method according to claim 1 , wherein the compound is of following general formula (Ia):

9. The method according to claim 1 , wherein said compound is selected from the following compounds:

and pharmaceutically acceptable salt and/or solvate thereof.

10. The method according to claim 1 , wherein the ErbB2 cancer patient that overexpresses ErbB2 is a patient with metastases.

11. The method according to claim 1 , wherein said ErbB2 dependent cancer is lung cancer, ovarian cancer, stomach cancer, bladder cancer, uterine cancer, pancreas cancer, liver cancer, kidney cancer, gastroeosophageal cancer, gastric cancer, colorectal cancer, female genital tract cancer, endometrial cancer, anal cancer, breast cancer or neurofibroma.

12. The method according to claim 11 , wherein said ErbB2 dependent cancer is ovarian cancer, pancreas cancer, gastroeosophageal cancer, gastric cancer, colorectal cancer, endometrial cancer, anal cancer or neurofibroma.

13. The method according to claim 11 , wherein said ErbB2 dependent cancer is ovarian cancer, gastric cancer or breast cancer.

14. The method according to claim 3 , wherein halo is Cl or F.

Assignees

• Centre Nat Rech Scient
• Inst Nat Sante Rech Med
• Univ Paris Descartes

Inventors

• Bourdoulous Sandrine
• Faure Camille

Classifications

• A61K31/497

  containing further heterocyclic rings · CPC title

• A61K31/41

  having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title

• C07D275/04

  condensed with carbocyclic rings or ring systems · CPC title

• C07D405/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• C07D409/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title